Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2022-01-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
国元证券股份有限公司关于安徽安科生物工程(集团)股份有限公司2021年持续督导培训情况的报告
Regulatory Filings Classification · 90% confidence The document is a report from a sponsoring institution (国元证券股份有限公司) about the continuous supervision training conducted for 安徽安科生物工程(集团)股份有限公司 in 2021. It details the training content, participants, and summary of the training session. The document does not contain financial statements, earnings data, or regulatory filings such as certifications or voting results. It is a specific report on a training activity related to regulatory compliance and supervision, which does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is also not a presentation or announcement but a report on a specific supervisory training event. Given the available categories, the closest match is Regulatory Filings (RNS) as a fallback for miscellaneous regulatory-related reports that do not fit other categories.
2022-01-28 Chinese
2021年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2021 annual performance forecast (业绩预告) for Anhui Anke Biotechnology Engineering (Group) Co., Ltd. It covers the expected net profit and revenue for the full fiscal year 2021 (January 1 to December 31, 2021). The text explicitly states that the financial data is preliminary, unaudited, and that the final audited figures will be disclosed in the 2021 Annual Report. The document is relatively short (2173 characters) and serves as a forward-looking earnings guidance rather than a full financial report. It does not contain actual audited financial statements or detailed financial analysis. This type of document is best classified as an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results or forecasts with key highlights only. FY 2021
2022-01-28 Chinese
关于董事、高级管理人员辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company director and senior management member. It details the resignation of Mr. Zheng Weiguo from his positions as director and vice president, the impact on the board, and the company's plans to fill the vacancy. There is no financial data, no mention of financial results, reports, or regulatory filings beyond this management change. This fits the category of Board/Management Information (MANG). The document length is short and focused solely on management changes, confirming the classification.
2022-01-24 Chinese
关于变更签字注册会计师的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the change of signing certified public accountants for the company's 2021 audit. It details the replacement of certain auditors and provides background information on the new signing auditors. The document does not contain any financial statements or audit results itself, but rather informs about a personnel change related to the audit process. This fits the category of Audit Report / Information (AR), which includes standalone audit reports and related information such as changes in auditors. The document is not a full annual report or audit report but an announcement about audit personnel changes, which is best classified under AR rather than a general regulatory filing or report publication announcement due to its specific audit-related content. FY 2021
2022-01-24 Chinese
关于合肥连山创新产业投资基金完成备案的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the completion of the filing of an investment fund with the China Securities Investment Fund Association. It details the establishment of a new investment fund, the company's participation as a limited partner, and the regulatory compliance of the fund. The document is short (797 characters) and serves as an announcement of a financing-related event rather than a detailed financial report or presentation. It does not contain financial statements or detailed financial data but rather informs about a capital/financing update related to the company's investment activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-01-07 Chinese
关于第七届监事会第十四次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a resolution passed by the supervisory board about waiving the preemptive rights to subscribe for capital increase in an associate company. It is a formal disclosure of a board decision and does not contain financial statements, audit information, or detailed financial results. It is not an annual or interim report, nor an earnings release. It is not a regulatory certification or a report publication announcement. The content fits best under a regulatory announcement category related to corporate governance decisions but not specifically a board or management change announcement. Given the nature of the announcement and the fallback rule, it is best classified as a Regulatory Filing (RNS).
2022-01-06 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.